Fig 5. Break-even analysis of preventive vaccination practice according to cost of attenuated-PRRSv on growth performance or magnitude of reduction on pigs/sow/year (PSY) due to attenuated PRRSv.
(A) Impact of margin over variable cost (MOVC) and production cost attributable to PRRSv on advantage to have prior PRRSv-immunity. (B) Impact of MOVC and PSY on advantage to have prior PRRSv-immunity.